Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

Exclusion Criteria

• •Any 5α-reductase inhibitors medications within the past 12 months before enrollment.
• •Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors.
• •Anticipated blood donation within the next 90 days.
• •Serum PSA levels of \>20ng/dl.
• •Clinical evidence of metastatic prostate cancer.
• •Two documented urinary tract infections in the past year
• •CHF, MI (within 6 months) or other symptomatic CVS disease
• •Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric)
• •Enrollment in other studies for any disease in the past 30 days
• •Significant urinary incontinence
• •Diagnosis of cancer that in not considered cured, except BCC of skin
• •Prior transurethral resection of the prostate with a large tissue defect.
• •History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology
• •Previous or concurrent radiotherapy, hormonal therapy or chemotherapy